Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Is antibiotic resistance a big deal?

Professor Brendan Gilmore discusses what action is being taken to win the "arms race" with bacteria.

Antibiotic resistance is a real problem, but is it the apocalyptic scenario painted by the media and politicians?

C+D spoke to Brendan Gilmore, professor of pharmaceutical microbiology at Queen's University Belfast, to answer this question and understand why this "ancient" phenomenon occurs. 

In this C+D clinical podcast you will learn:

  • The different mechanisms of resistance 
  • How human and animal use has "driven" resistance
  • What steps should be taken to keep ahead of resistance
  • The deficit in new antibiotic production and why "we need a sustainable pipeline of antibiotics"
  • What research is being undertaken in this area
  • The role of the pharmacist in helping to halt the emergence of antibiotic resistance

What do you do to help prevent antibiotic resistance?

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD008324

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel